Having trouble accessing articles? Reset your cache.

PecFent: Phase III data

A double-blind, placebo-controlled, crossover, international Phase III trial in 114 patients with breakthrough cancer pain showed that PecFent met the primary endpoint of a

Read the full 246 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE